Transaction · 0001628280-26-059882

Struthers Richard Scott

Struthers Richard Scott, PRES, CEO, reported a transaction classified as return at Crinetics Pharmaceuticals, Inc. involving 100000.000000 shares for an estimated $8500000.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DPRES, CEO
CRNXCrinetics Pharmaceuticals, Inc.
Trade date
Sep 01, 2026
Filing date
Sep 01, 2026
View on SEC Insider profile
Estimated value-$8.50MShares × reported price
Shares traded100k$85.00 per share
Holdings after0Indirect · By Family Trust 4
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CRNX price since this filing

Daily closing prices, with the filing date and available return windows
CRNX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -1.7%1w ago -0.2%1d ago +0.0%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
return
Code D
Identifier
0001628280-26-059882
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 01, 2026, 08:52 PM · 0d delay
Shares
100,000 sh
$85.00 per share
Estimated value
-$8.50M
Computed from shares × price
Holdings after
0 sh
Indirect · By Family Trust 4
Filing-only score

+4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 0

    Filing reported within two business days of the transaction.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President & CEO

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceut…

  2. F2

    The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive…

  3. F3

    The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effectiv…

  4. F4

    The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Co…

Original filing · 0001628280-26-059882
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CRNX